Osteoporosis in men: Recent progress

Endocrine

Volumn 44, Issue 1, 2013, Pages 40-46

  Adler, Robert A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bisphosphonates; Dual energy x ray absorptiometry; Fracture; Men; Osteoporosis

Indexed keywords

ALENDRONIC ACID; DENOSUMAB; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RISEDRONIC ACID; SEX HORMONE; STRONTIUM RANELATE; TESTOSTERONE; ZOLEDRONIC ACID;

DISEASE CLASSIFICATION; EVIDENCE BASED PRACTICE; FRACTURE; FRAGILITY FRACTURE; HUMAN; LONGEVITY; MALE; OSTEOPOROSIS; PATHOPHYSIOLOGY; PATIENT IDENTIFICATION; PRACTICE GUIDELINE; PRIMARY OSTEOPOROSIS; PRIORITY JOURNAL; PUBLICATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SECONDARY OSTEOPOROSIS;

ANIMALS; ENDOCRINOLOGY; FEMALE; HUMANS; MALE; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; SEX CHARACTERISTICS;

EID: 84881135703     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-013-9880-7     Document Type: Review

References (66)

1. R. Burge, B. Dawson-Hughes, D.H. Solomon, J.B. Wong, A. King, A.N. Toteston, Incidence and economic burden of osteoporosis-related fracture and subsequent fracture in men and women. JAMA 22, 365-475 (2007)
2. S. Khosla, L.J. Melton III, E.J. Atkinson, W.M. O'Falon, Relationship of serum sex steroids to longitudinal changes in bone density in young versus elderly men. J. Clin. Endocrinol. Metab. 86, 3555-3561 (2001)
3. T.P. van Staa, E.M. Dennison, H.G. Leufkens, C. Cooper, Epidemiology of fractures in England and Wales. Bone 29, 517-522 (2001)
4. R.B. Hopkins, E. Pullenayegum, R. Goeree, J.D. Adachi, A. Papaioannou, W.E. Leslie, J.E. Tarride, L. Thabane, Estimation of the lifetime risk of hip fracture for women and men in Canada. Osteoporos. Int. 23, 921-927 (2012)
5. A.C. Feldstein, G. Nichols, E. Orwoll, P.J. Elmer, D.H. Smith, M. Herson, M. Aickin, The near absence of osteoporosis treatment in older men with fractures. Osteoporos. Int. 16, 953-962 (2005)
6. J.R. Center, D. Bliuc, T.V. Nguyen, J.A. Eisman, Risk of subsequent fracture after low-trauma fracture in men and women. JAMA 24, 387-394 (2007)
7. J.E. Block, H. Stubbs, Hip fracture-associated mortality reconsidered. Calcif. Tissue Int. 61, 84 (1997)
8. T.P. van Staa, H.G. Leufkens, L. Abenhaim, B. Zhang, C. Cooper, Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxf.) 39, 1383-1389 (2000)
9. R.A. Adler, M.C. Hochberg, Glucocorticoid-induced osteoporosis in men. J. Endocrinol. Investig. 34, 481-484 (2011)
10. G.L. Lu-Yao, P.C. Albertsen, D.F. Moore, W. Shih, Y. Lin, R.S. DiPaola, S.L. Yao, Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 300, 173-181 (2008)
11. V.B. Shahinian, Y.F. Kuo, J.L. Freeman, J.S. Goodwin, Risk of fracture after androgen deprivation for prostate cancer. N. Engl. J. Med. 352, 154-164 (2005)
12. B.L. Riggs, L.J. Melton III, Involutional osteoporosis. N. Engl. J. Med. 314, 1676-1686 (1986)
13. R.A. Adler, Osteoporosis in men: insights for the clinician. Ther Adv Musculoskelet Dis 3, 191-200 (2011)
14. J.A. Kanis, H. Johansson, A. Oden, B. Dawson-Hughes, L.J. Melton III, E.V. McCloskey, The effects of a FRAX revision for the USA. Osteoporos. Int. 21, 35-40 (2010)
15. N.D. Nguyen, S.A. Frost, J.R. Center, J.A. Eisman, T.V. Nguyen, Development of a nomogram for individualizing hip fracture risk in men and women. Osteoporos. Int. 18, 1109-1117 (2008)
16. C.S. Ryan, V.I. Petkov, R.A. Adler, Osteoporosis in men: the value of laboratory testing. Osteoporos. Int. 22, 1845-1853 (2011)
17. E. Romagnoli, R. Del Fiacco, S. Russo, S. Piemonte, F. Fidanza, F. Colapietro, D. Diacinti, C. Cipriani, S. Minisola, Secondary osteoporosis in men and women: clinical challenge of an unresolved issue. J. Rheumatol. 38, 1671-1679 (2011)
18. L.E. Ryan, S.W. Ing, Idiopathic hypercalciuria and bone health. Curr. Osteoporos. Rep. 10, 286-295 (2012)
19. P. Vestergaard, L. Rejnmark, L. Mosekilde, Fracture risk associated with the use of morphine and opiates. J. Intern. Med. 260, 76-87 (2006)
20. S.M. Harman, E.J. Metter, J.D. Tobin, J. Pearson, M.R. Blackman, Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J. Clin. Endocrinol. Metab. 86, 724-731 (2001)
21. J.M. Kaufman, A. Vermeulen, The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr. Rev. 26, 833-876 (2005)
22. G. Sartorius, S. Spasevska, A. Idan, L. Turner, E. Forbes, A. Zamojska, C.A. Allan, L.P. Ly, A.J. Conway, R.I. McLachlan, D.J. Handelsman, Serum testosterone, dihydrotestosterone and estradiol concentrations in older men self-reporting very good health: the healthy man study. Clin. Endocrinol. 77, 755-763 (2012)
23. P. Dandona, S. Dhindsa, Update: hypogonadotropic hypogonadism in type 2 diabetes and obesity. J. Clin. Endocrinol. Metab. 96, 2643-2651 (2011)
24. K.M. Wiren, A. Chapman Evans, X.W. Zhang, Osteoblast differentiation influences androgen and estrogen receptor-alpha and -beta expression. J. Endocrinol. 175, 683-694 (2002)
25. H. Lee, J.S. Finkelstein, M. Miller, S.J. Comeaux, R.I. Cohen, B.Z. Leder, Effects of selective testosterone and estradiol withdrawal on skeletal sensitivity to parathyroid hormone in men. J. Clin. Endocrinol. Metab. 91, 1069-1075 (2006)
26. D. Merlotti, L. Gennari, K. Stolakis, R. Nuti, Aromatase activity and bone loss in men. J. Osteoporos. 2011, 230671 (2011). doi: 10.4061/2011/230671
27. C.M. Nielson, L.M. Marshall, A.L. Adams, E.S. LeBlanc, P.M. Cawthon, K. Ensrud, E. Barrett-Connor, E.S. Orwoll, Osteoporotic Fractures in Men Study Research Group. BMI and fracture risk in older men: the osteoporotic fractures in men study (MrOS). J. Bone Miner. Res. 26, 496-502 (2011)
28. L.A. Fitzpatrick, Secondary causes of osteoporosis. Mayo Clin. Proc. 77, 453-468 (2002)
29. R.A. Adler, Laboratory testing for secondary osteoporosis evaluation. Clin. Biochem. 45, 894-900 (2012)
30. G. Mazziotti, T. Porcelli, M. Mormando, E. De Menis, A. Bianchi, C. Mejia, T. Mancini, L. De Marinis, A. Giiustina, Vertebral fractures in males with prolactinoma. Endocrine 39, 288-293 (2011)
31. C. Torti, G. Mazziotti, P.A. Soldini, E. Foca, R. Maroldi, D. Gotti, G. Carosi, A. Giustina, High prevalence of radiological vertebral fractures in HIV-infected males. Endocrine 41, 512-517 (2012)
32. T.T. Dam, S. Harrison, H.A. Fink, J. Ramsdell, E. Barrett-Connor, Osteoporotic Fractures in Men (MrOS) Research Group, Bone mineral density and fractures in older men with chronic obstructive pulmonary disease or asthma. Osteoporos. Int. 21, 1341-1349 (2010)
33. G. Mazziotti, E. Canalis, A. Giustina, Drug-induced osteoporosis: mechanisms and clinical implications. Am. J. Med. 123, 877-884 (2010)
34. C.E. Lewis, S.K. Ewing, B.C. Taylor, J.M. Shikany, H.A. Fink, K.E. Ensrud, E. Barrett-Connor, S.R. Cummings, E.S. Orwoll, Osteoporotic Fractures in Men (MrOs) Study Research Group, Predictors of non-spine fracture in elderly men: the MrOS Study. J. Bone Miner. Res. 22, 211-219 (2007)
35. J.A. Cauley, G. El Hajj Fuleihan, A. Arabi, S. Fujiwara, S. Ragi-Eis, A. Calderon, S.B. Chionh, Z. Chen, J.R. Curtis, M.E. Danielson, D.A. Hanley, H. Kroger, A.W. Kung, O. Lesnyak, J. Nieves, W. Pluskiewicz, R. El Rassi, S. Silverman, A.M. Schott, R. Rizzoli, M. Luckey, FRAX Position Conference Members, Official positions for FRAX clinical regarding international differences from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis on FRAX. J. Clin. Densitom. 14, 240-262 (2011)
36. J.P. Bilezikian, S.J. Silverberg, Normocalcemic primary hyperparathyroidism. Arq. Bras. Endocrinol. Metab. 54, 106-109 (2010)
37. N. Binkley, R.A. Adler, Dual-energy X-ray absorptiometry (DXA) in men, in Osteoporosis in Men, 2nd edn., ed. by E.S. Orwoll, J.P. Bilezikian, D. Vanderschueren (Academic Press, New York, 2010), pp. 525-540
38. T. Isaksen, C.S. Nielsen, S.E. Christensen, P.H. Nissen, L. Heickendorff, L. Mosekilde, Forearm bone mineral density in familial hypocalciuric hypercalcemia and primary hyperparathyroidism: a comparative study. Calcif. Tissue Int. 89, 285-294 (2011)
39. D.K. Dhanwal, N. Kochupillai, N. Gupta, C. Cooper, E.M. Dennison, Hypovitaminosis D and bone mineral metabolism and bone density in hyperthyroidism. J. Clin. Densitom. 13, 462-466 (2010)
40. D. Mittan, S. Lee, E. Miller, R.C. Perez, J.W. Basler, J.M. Bruder, Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J. Clin. Endocrinol. Metab. 87, 3656-3661 (2002)
41. J.A. Kanis, L.J. Melton III, C. Christiansen, C.C. Johnston, N. Khaltaev, The diagnosis of osteoporosis. J. Bone Miner. Res. 9, 1137-1141 (1994)
42. J.A. Kanis, G. Bianchi, J.P. Bilezikian, J.M. Kaufman, S. Khosla, E. Orwoll, E. Seeman, Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos. Int. 22, 2789-2798 (2011)
43. P.L. Selby, P.L. Davies, J.E. Adams, Do men and women fracture bones at similar bone densities? Osteoporos. Int. 11, 153-157 (2000)
44. R.A. Adler, Osteoporosis in men: what has changed? Curr. Osteoporos. Rep. 9, 31-35 (2011)
45. M.G. Donaldson, P.M. Cawthon, L.Y. Lui, J.T. Schousboe, K.E. Ensrud, B.C. Taylor, J.A. Cauley, T.A. Hillier, T.T. Dam, J.R. Curtis, D.M. Black, D.C. Bauer, E.S. Orwoll, S.R. Cummings, Osteoporotic Fractures in Men (MrOS) Study Group, Estimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US National Osteoporosis Foundation Guidelines. J. Bone Miner. Res. 25, 1506-1511 (2010)
46. G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatment for osteoporosis. Endocrine 41, 58-69 (2012)
47. E.S. Orwoll, M. Ettinger, S. Weiss, P. Miller, D. Kendler, J. Graham, S. Adami, K. Weber, R. Lorenc, P. Pietschmann, K. Vandormael, A. Lombardi, Alendronate for the treatment of osteoporosis in men. N. Engl. J. Med. 343, 604-610 (2000)
48. L.H. Klotz, I.Y. McNeill, M. Kebabdjian, L. Zhang, J. Chin, Canadian Urology Research Consortium, A phase 3, double-blind, randomized, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the cancer and osteoporosis research with alendronate and leuprolide (CORAL) study. Eur. Urol. doi: 10.1016/j.eururu.2012.09.007
49. S. Boonen, E.S. Orwoll, D. Wenderoth, K.J. Stoner, R. Eusebio, P.D. Delmas, Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J. Bone Miner. Res. 24, 719-725 (2009)
50. P. Taxel, R. Dowsett, L. Richter, P. Fall, A. Klepinger, P. Albertsen, Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer. BJU Int. 106, 1473-1476 (2010)
51. E.S. Orwoll, N.C. Binkley, E.M. Lewiecki, U. Gruntmanis, M.A. Fries, G. Dasic, Efficacy and safety of monthly ibandronate in men with low bone density. Bone 46, 970-976 (2010)
52. E.S. Orwoll, P.D. Miller, J.D. Adachi, J. Brown, R.A. Adler, D. Kendler, C. Bucci-Rechtweg, A. Readie, P. Messenbrink, R.S. Weinstein, Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J. Bone Miner. Res. 25, 2239-2250 (2010)
53. S. Boonen, J.Y. Reginster, J.M. Kaufman, K. Lippuner, J. Zanchetta, B. Langdahl, R. Rizzoli, S. Lipschitz, H.P. Dimai, R. Witvrouw, E. Eriksen, K. Brixen, L. Russo, F. Claessens, P. Papanastasiou, O. Antunez, G. Su, C. Bucci-Rechtweg, J. Hruska, E. Incera, D. Vanderschueren, E. Orwoll, Fracture risk and zoledronic acid therapy in men with osteoporosis. N. Engl. J. Med. 367, 1714-1723 (2012)
54. K. Sinningen, E. Tsourdi, M. Rauner, T.D. Rachner, C. Hamann, L.C. Hofbauer, Skeletal and extraskeletal actions of denosumab. Endocrine 42, 52-62 (2012)
55. E. Orwoll, C.S. Teglbjaerg, B.L. Langdahl, R. Chapurlat, E. Czerwinski, D.L. Kendler, J.Y. Reginster, A. Kivitz, E.M. Lewiecki, P.D. Miller, M.A. Bolognese, M.R. McClung, H.G. Bone, P. Ljimggrem, B. Abrahamsne, U. Gruntmanis, Y.C. Yang, R.B. Wagman, S. Siddhanti, A. Grauer, J.W. Hall, S. Boonen, A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J. Clin. Endocrinol. Metab. 97, 3161-3169 (2012)
56. M.R. Smith, B. Egerdie, N.H. Toriz, R. Feldman, T.L. Tammela, F. Saad, J. Heracek, M. Szwedowski, C. Ke, A. Kupic, B.Z. Leder, C. Goessl, Denosumab HALT Prostate Cancer Study Group, Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 361, 745-755 (2009)
57. N.E. Cusano, A.G. Costa, B.C. Silva, J.P. Bilezikian, Therapy of osteoporosis in men with teriparatide. J. Osteoporos. 2011, 463675 (2011). doi: 10.4061/2011/463675
58. J.M. Kaufman, E. Orwoll, S. Goemaere, J. San Martin, A. Hossain, G.P. Dalsky, R. Linsday, B.H. Mitlak, Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos. Int. 16, 510-516 (2005)
59. J.D. Ringe, A. Dorst, P. Farahmand, Efficacy of strontium ranelate on bone mineral density in men with osteoporosis. Arzneimittelforschung 60, 267-272 (2010)
60. H.M. Behre, S. Kliesch, E. Leifke, T.M. Link, E. Nieschlag, Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J. Clin. Endocrinol. Metab. 82, 2386-2390 (1997)
61. J.K. Amory, N.B. Watts, K.A. Easley, P.R. Sutton, B.D. Anawalt, A.M. Matsumoto, W.J. Bremer, J.L. Tenover, Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J. Clin. Endocrinol. Metab. 89, 503-510 (2004)
62. P.J. Snyder, H. Peachey, P. Hannoush, J.A. Berlin, L. Loh, J.H. Holmes, A. Dlewati, J. Staley, J. Santanna, S.C. Kapoor, M.F. Attie, J.G. Haddad Jr., B.L. Strom, Effect of testosterone treatment on bone mineral density in men over 65 years of age. J. Clin. Endocrinol. Metab. 84, 1966-1972 (1999)
63. N.B. Watts, R.A. Adler, J.P. Bilezikian, M.T. Drake, R. Eastell, E.S. Orwoll, J.S. Finkelstein, Osteoporosis in men: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 97, 1802-1822 (2012)
64. J. Compston, Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. Osteoporos. Int. 22, 2951-2961 (2011)
65. S.V. Reddy, S.K. Gupta, Atypical femoral shaft fractures in a patient with non-metastatic prostate cancer on zoledronic acid therapy: effect of therapy or coincidence? Singap. Med. J. 53, e52-e54 (2012)
66. N.B. Watts, D.L. Diab, Long-term use of bisphosphonates in osteoporosis. J. Clin. Endocrinol. Metab. 95, 1555-1565 (2010)